NEW YORK – Nucleai, a startup maker of a technology platform for precision oncology research and clinical decision support, said Tuesday that it has raised $6.5 million in the initial stage of a Series A funding round.
Swiss biopharmaceutical company Debiopharm led the investment, with participation from Vertex Ventures and Grove Ventures. As part of this investment, Debiopharm will collaborate with Nucleai on efforts to accelerate the discovery of biomarkers for oncology drug response.